Pineoblastoma

Pineoblastoma is a rare, highly aggressive embryonal tumor of the pineal gland, a small endocrine organ located deep in the center of the brain. It belongs to the group of primitive neuroectodermal tumors (PNETs) and is classified as a WHO grade IV central nervous system malignancy. Pineoblastoma predominantly affects young children, though it can occur at any age. The tumor arises from immature cells of the pineal gland and tends to grow rapidly, often spreading through the cerebrospinal fluid (CSF) to other parts of the brain and spinal cord (leptomeningeal dissemination). The most common presenting symptoms result from obstruction of cerebrospinal fluid flow, leading to hydrocephalus with signs of increased intracranial pressure such as headaches, nausea, vomiting, and lethargy. Patients may also develop Parinaud syndrome (difficulty with upward gaze and other eye movement abnormalities) due to compression of the tectal plate. In infants, an enlarging head circumference and bulging fontanelle may be observed. Visual disturbances, ataxia, and altered consciousness can also occur as the tumor progresses. Treatment typically involves a multimodal approach including maximal safe surgical resection, craniospinal irradiation, and intensive chemotherapy. In very young children (typically under 3-4 years), radiation therapy may be delayed or modified due to its detrimental effects on the developing brain, with chemotherapy used as the primary adjuvant treatment. Pineoblastoma is notably associated with trilateral retinoblastoma syndrome, in which children with hereditary bilateral retinoblastoma (carrying germline RB1 mutations) develop a pineoblastoma. Despite aggressive treatment, the prognosis remains guarded, with five-year survival rates varying considerably depending on age at diagnosis, extent of disease, and treatment received. Ongoing clinical trials continue to explore novel therapeutic strategies to improve outcomes.

Common questions about Pineoblastoma